Chinachote Teerapakpinyo

Dr. Chinachote Teerapakpinyo


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2019 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
SSSomruetai Shuangshoti
Somruetai Shuangshoti
PTPaveen Tadadontip
Paveen Tadadontip
PTPiti Techavichit
Piti Techavichit
PTPaul S. Thorner
Paul S. Thorner
SSShanop Shuangshoti
Shanop Shuangshoti
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo
Molecular subtyping of medulloblastoma (MB) has become increasingly important for prognosis and management. Typically this involves detailed molecular genetic testing which may not be available in all centers. The purpose of the present study was to find a simplified approach to assign molecular subtypes of MB for routine use in centers with more limited resources. The molecular subtypes of MBs from 32 Thai patients, aged 0.5 to 35 years, were first determined by NanoString. These results were then compared with those obtained using a combination of limited immunohistochemistry (IHC) (β-catenin, GAB-1, YAP-1, p75-NGFR, OTX2) and CTNNTB exon 3 mutation analysis. By NanoString assay, there were 6 MBs (19%) in the wingless (WNT) group, 8 (25%) in the sonic hedgehog (SHH) group, 7 (22%) in group 3, and 11 (34%) in group 4. Although β-catenin immunostaining missed 4/6 WNT MBs, CTNNTB mutation analysis confirmed all WNT MB cases with amplifiable DNA. The IHC panel correctly assigned all the other molecular subtypes, except for 1 MB in group 4. Thus, our protocol was able to correctly categorized 31/32 cases or 97% of cases. Our study is the first to report molecular subtypes of MB in Southeast Asia. We found that molecular subgroups of MBs can be reliably assigned using a limited IHC panel of β-catenin, GAB-1, YAP-1, p75-NGFR, OTX2, together with CTNNTB exon 3 mutation analysis. This simplified approach incurs lower cost and faster turnaround time compared with more elaborate molecular methodologies and should be beneficial to centers with reduced laboratory resources.

22 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
LRLucksica Ruangapirom
Lucksica Ruangapirom
NSNannapat Sutivijit
Nannapat Sutivijit
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo
AMApiwat Mutirangura
Apiwat Mutirangura
CDChatchanan Doungkamchan
Chatchanan Doungkamchan
Personalized neoantigen-based cancer vaccines have been shown to be safe and immunogenic in cancer patients; however, the manufacturing process can be costly and bring about delays in treatment. Using off-the-shelf cancer vaccines targeting shared neoantigens may circumvent these problems. Unique mutational signatures and similar phenotypes found among BRCA1-mutated breast cancer make it an ideal candidate for discovering shared neoantigens within the group. We obtained genome sequencing data of breast cancer samples with or without somatic BRCA1 mutations (BRCA1-positive and BRCA1-negative, respectively) from the three public cancer databases; The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Catalogue of Somatic Mutations in Cancer (COSMIC); and from three studies with whole genome/exome sequencing data of samples with germline BRCA1 mutations. Data were analyzed separately within the same database/cohort. We found PIK3CA H1047R, E545K, E542K, and N345K recurrently in BRCA1-negative groups across all databases, whereas recurrent somatic mutations in BRCA1-positive groups were discordant among databases. For germline BRCA1-mutated breast cancer, TP53 R175H was unanimously the most frequent mutation among the three germline cohorts. Our study provides lists of potential shared neoantigens among BRCA1-related breast cancer, which may be used in developing off-the-shelf neoantigen-based vaccines.

20 June 2022 in Neuropathology
Verified
Journal Article
Closed access
SSSakun Santisukwongchote
Sakun Santisukwongchote
PTPaul Scott Thorner
Paul Scott Thorner
TDTayard Desudchit
Tayard Desudchit
PTPiti Techavichit
Piti Techavichit
NJNutchawan Jittapiromsak
Nutchawan Jittapiromsak
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo

10 April 2023 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
ABAtthaporn Boongird
Atthaporn Boongird
NLNopphon Lekcharoensombat
Nopphon Lekcharoensombat
AJArtit Jinawath
Artit Jinawath
TTTalent Theparee
Talent Theparee
NJNutchawan Jittapiromsak
Nutchawan Jittapiromsak
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo

1 July 2021 in Pathology - Research and Practice
Verified
Journal Article
Closed access
SSSakun Santisukwongchote
Sakun Santisukwongchote
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo
PCPiyamai Chankate
Piyamai Chankate
PTPiti Techavichit
Piti Techavichit
ABAtthaporn Boongird
Atthaporn Boongird
SSShanop Shuangshoti
Shanop Shuangshoti

1 September 2019 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
SSSomruetai Shuangshoti
Somruetai Shuangshoti
CTChinachote Teerapakpinyo
Chinachote Teerapakpinyo
Adenomatous polyps of the vulva and vagina are extremely rare. We report a case of a 74-yr-old women with a tubulovillous adenoma occurring in the vagina, and a second one occurring later in the vulva. Tumor cells in both lesions were CK7−, CK20+, CDX-2+, and showed intact mismatch-repair proteins. A G13D (c.38G>A, p.Gly13Asp) mutation in the KRAS gene was identified in both masses. As well, a novel frameshift truncating mutation (c.4320delA, p.Pro1441fsTer32) in the APC gene was detected only in the vaginal mass, ruling out the possibility that the vulvar mass was a local recurrence of the vaginal mass. This is the first identification of KRAS and APC gene mutations in adenomatous polyps involving the female lower genital tract.